ZA873215B - Htlv-iii/lav virus related peptides,antibodies to the peptides,vaccines,passive and active immunization against aids virus and diagnostic test for the serological detection of aids virus - Google Patents

Htlv-iii/lav virus related peptides,antibodies to the peptides,vaccines,passive and active immunization against aids virus and diagnostic test for the serological detection of aids virus

Info

Publication number
ZA873215B
ZA873215B ZA873215A ZA873215A ZA873215B ZA 873215 B ZA873215 B ZA 873215B ZA 873215 A ZA873215 A ZA 873215A ZA 873215 A ZA873215 A ZA 873215A ZA 873215 B ZA873215 B ZA 873215B
Authority
ZA
South Africa
Prior art keywords
virus
htlv
iii
aids
lav
Prior art date
Application number
ZA873215A
Other languages
English (en)
Inventor
L. Goldstein Allan
Sun Wang Su
Original Assignee
Viral Technologies Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viral Technologies Inc. filed Critical Viral Technologies Inc.
Publication of ZA873215B publication Critical patent/ZA873215B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036Retroviridae, e.g. leukemia viruses
    • C07K16/1045Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1054Lentiviridae, e.g. HIV, FIV, SIV gag-pol, e.g. p17, p24
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/14011Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16211Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA873215A 1986-05-19 1987-05-05 Htlv-iii/lav virus related peptides,antibodies to the peptides,vaccines,passive and active immunization against aids virus and diagnostic test for the serological detection of aids virus ZA873215B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86459986A 1986-05-19 1986-05-19

Publications (1)

Publication Number Publication Date
ZA873215B true ZA873215B (en) 1987-10-28

Family

ID=25343634

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA873215A ZA873215B (en) 1986-05-19 1987-05-05 Htlv-iii/lav virus related peptides,antibodies to the peptides,vaccines,passive and active immunization against aids virus and diagnostic test for the serological detection of aids virus

Country Status (17)

Country Link
EP (1) EP0246829B1 (xx)
JP (3) JPH089636B2 (xx)
KR (1) KR910002690B1 (xx)
CN (1) CN87103568A (xx)
AT (1) ATE100469T1 (xx)
AU (1) AU606595B2 (xx)
DE (1) DE3788822T2 (xx)
DK (1) DK173040B1 (xx)
ES (1) ES2061495T3 (xx)
GB (1) GB2190679B (xx)
IE (1) IE60274B1 (xx)
IL (1) IL82471A (xx)
IN (1) IN167198B (xx)
MX (1) MX167236B (xx)
NZ (1) NZ220200A (xx)
PH (1) PH26239A (xx)
ZA (1) ZA873215B (xx)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1219232A (en) * 1983-08-17 1987-03-17 Richard A. Lerner Polypeptide-induced monoclonal receptors to protein ligands
US4863730A (en) * 1986-03-21 1989-09-05 Cenfold Holdings, S.A. Immunotherapy for AIDS patients
DE346022T1 (de) * 1988-06-10 1990-05-23 Medical Research Council, London Peptidfragmente von hiv.
US5219725A (en) 1988-12-05 1993-06-15 Idexx Laboratories Incorporated Monoclonal antibodies to feline-t-lymphotropic lentivirus
ATE105413T1 (de) * 1989-02-01 1994-05-15 Du Pont Hiv p17-test fuer die ueberwachung des verlaufs von aids.
WO1990013573A1 (en) * 1989-05-08 1990-11-15 Idexx Corporation Polypeptides of feline t-cell lymphotropic lentivirus
NZ235538A (en) * 1989-10-12 1992-06-25 Viral Technologies Inc Peptides immunoreactive with antibodies to hiv p17; carrier-bound peptides, vaccines, immunoassay and a method for forming antibody enriched sera
DE4106686A1 (de) * 1991-03-02 1992-09-03 Daimler Benz Ag Verriegelungsanordnung
FR2734281B1 (fr) * 1995-05-18 1997-07-25 Commissariat Energie Atomique Fragments d'acide nucleique derives du genome du virus vih-1, peptides correspondants et leurs applications en tant que reactifs d'evaluation du risque de transmission materno-foetale du vih-1
US6093400A (en) * 1996-08-09 2000-07-25 Cel Sci Corporation Modified HGP-30 peptides, conjugates, compositions and methods of use
EP0969864A1 (en) 1996-08-09 2000-01-12 Viral Technologies, Inc. Hiv p-17 peptide fragment, compositions containing and methods for producing and using same
US6818392B2 (en) 2000-12-06 2004-11-16 Abbott Laboratories Monoclonal antibodies to human immunodeficiency virus and uses thereof
DE60045249D1 (de) 2000-12-21 2010-12-30 Semiconductor Components Ind Verfahren und Vorrichtung zur Reduktion von Schaltgeräuschen in einem Transformator eines Schaltnetzteils

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4264571A (en) * 1979-01-22 1981-04-28 George Washington University Radioimmunoassay of thymosin α1
DE2919592A1 (de) * 1979-05-15 1981-01-15 Max Planck Gesellschaft Verfahren zur herstellung von thymosin- alpha 1 und derivaten davon
US4339427A (en) * 1980-04-14 1982-07-13 Hoffmann-La Roche Inc. Radioimmunoassay of thymosinα
US4517119A (en) * 1983-04-04 1985-05-14 Hoffmann-La Roche Inc. Synthesis of thymosin α1
US4504415A (en) * 1983-04-04 1985-03-12 Hoffman-La Roche Inc. Synthesis of thymosin α1 and desacetyl thymosin α1

Also Published As

Publication number Publication date
ATE100469T1 (de) 1994-02-15
EP0246829A3 (en) 1989-08-09
AU606595B2 (en) 1991-02-14
GB8711567D0 (en) 1987-06-17
IL82471A (en) 1993-02-21
DK173040B1 (da) 1999-11-29
JPH0925300A (ja) 1997-01-28
KR910002690B1 (ko) 1991-05-03
EP0246829B1 (en) 1994-01-19
JPS6327498A (ja) 1988-02-05
JPH089636B2 (ja) 1996-01-31
DE3788822T2 (de) 1994-07-28
DK245287A (da) 1987-11-20
MX167236B (es) 1993-03-11
KR870011154A (ko) 1987-12-21
PH26239A (en) 1992-04-01
IE60274B1 (en) 1994-06-29
ES2061495T3 (es) 1994-12-16
GB2190679A (en) 1987-11-25
GB2190679B (en) 1991-02-20
IE871289L (en) 1987-11-19
IL82471A0 (en) 1987-11-30
JP2598245B2 (ja) 1997-04-09
NZ220200A (en) 1990-08-28
EP0246829A2 (en) 1987-11-25
DE3788822D1 (de) 1994-03-03
DK245287D0 (da) 1987-05-14
AU7313587A (en) 1987-11-26
IN167198B (xx) 1990-09-15
CN87103568A (zh) 1988-01-27
JPH083200A (ja) 1996-01-09

Similar Documents

Publication Publication Date Title
Nara et al. Persistent infection of chimpanzees with human immunodeficiency virus: serological responses and properties of reisolated viruses
LYERLY et al. Anti-GP 120 antibodies from HIV seropositive individuals mediate broadly reactive anti-HIV ADCC
Jiang et al. Enhancement of human immunodeficiency virus type 1 infection by antisera to peptides from the envelope glycoproteins gp120/gp41.
IL82471A (en) Aids virus related peptides, antibodies to the peptides, vaccines, passive and active immunization against aids virus and diagnostic test for the serological detection of the aids virus
WO1987007616A1 (en) Peptides involved in the pathogenesis of hiv infection
Haynes et al. Induction of HIVMN neutralizing antibodies in primates using a prime-boost regimen of hybrid synthetic gp120 envelope peptides.
Kovacs et al. Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.
FI101797B (fi) STLV-III-virukseen liittyvät polypeptidit, diagnostiset järjestelmät j a määritysmenetelmät
US5017688A (en) Peptides involved in the pathogenesis of HIV infection
DE69110891T2 (de) Peptide und analoge und mischungen davon zum nachweis der gegen die viren htlv-1 und htlv-ii gerichteten antikörper.
Lee et al. Epstein‐Barr virus isolates with the major HLA B35. 01‐restricted cytotoxic T lymphocyte epitope are prevalent in a highly B35. 01‐positive African population
BÖTTIGER et al. Cross-neutralizing antibodies against HIV-1 (HTLV-IIIB and HTLV-IIIRF) and HIV-2 (SBL-6669 and a new isolate SBL-K135)
US6093400A (en) Modified HGP-30 peptides, conjugates, compositions and methods of use
Krook et al. HTLV-II among injecting drug users in Stockholm
Kanner et al. Human retroviral env and gag polypeptides: serologic assays to measure infection.
DK0426314T3 (da) HIV-relaterede peptider
DE3886032T2 (de) Hiv-1-verwandte polypeptide, diagnosesysteme und testverfahren.
RU96116005A (ru) Штамм hominis immunodeficiti virus (hiv-i) вич-i/россия/гм-12-95 (ru1295) субтипа в для диагностических и вакцинных препаратов
US4943627A (en) Peptides involved in the pathogenesis of HIV infection
Palker et al. Purification of envelope glycoproteins of human T cell lymphotropic virus type I (HTLV-I) by affinity chromatography
KR930008448B1 (ko) T-4수용체에 대한 결합을 억제하며, 면역원으로서 작용하는 소형 펩티드
HARAOA et al. Serological differences between human T-lymphotropic virus type-I (HTLV-I) and HTLV-III/LAV
EP0323424A3 (en) Peptide corresponding to hiv-env 583-599, and analogs thereof and applications of the peptides
TH9844EX (th) เพพไทด์ที่สัมพันธุ์ hiv
TH9844A (th) เพพไทด์ที่สัมพันธุ์ hiv